Clinical Trial NameClinical Trial Full TitlePrincipal InvestigatorProject site statusClinical trials gov number
(AbbVie) M16-191A Randomized, Open-Label, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib Alone In Subjects With MyelofibrosisLeber, Dr BrianOpen to recruitmentNCT04472598
(AbbVie) M19-708 / VIALE-MRandomized, Open-label, 2-Arm, Multicenter, Phase 3 Study of Venetoclax and Azacitidine Versus Best Supportive Care as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M)Leber, Dr BrianOpen to recruitmentNCT04102020
(AbbVie) M20-178 / TRANSFORM-2A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in
Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory
Myelofibrosis (TRANSFORM-2)
Leber, Dr BrianOpen to recruitmentNCT04468984
(Celgene) ACE-536-MDS-002 / COMMANDSA Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Subjects Who Require Red Blood Cell TransfusionsLeber, Dr BrianOpen to recruitmentNCT03682536
(Constellation) CPI-0610-02 / MANIFEST studyA Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis)Leber, Dr BrianOpen to recruitmentNCT02158858
(Horizon Health Network) The M4 Study The Terry Fox Pan-Canadian Multiple Myeloma Molecular Monitoring Cohort Study (The M4 Study) Mian, Dr HiraOpen to recruitmentNCT03421132
(Janssen) 68284528MMY3004/CARTITUDE 5A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd)
followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy
Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd)
followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly
Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as
Initial Therapy
Aljama, Dr MohammedOpen to recruitmentNCT04923893
(McMaster) CTTC 1901 / OZM-099A Randomized Pilot Trial comparing Anti-Thymocyte Globulin (ATG) with ATG plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis against Acute and Chronic Graft Versus Host Disease (GVHD) in Matched Donor Hematopoietic Cell Transplants (HCT)Walker, Dr IrwinOpen to recruitmentNCT04202835
(Novartis) CABL001J12301A phase III, multi-center, open-label, randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic PhaseLeber, Dr BrianOpen to recruitmentNCT04971226
(SHSC) 3242 / BRAWMA Multi-Center, Open-Label, Single-Arm Phase II Trial of Bendamustine, Rituximab and the Second Generation BTK Inhibitor Acalabrutinib in Previously Untreated Waldenstrom’s MacroglobulinemiaAljama, Dr MohammedOpen to recruitmentNCT04624906
CMRG 007 / MCRN 007 / ALGONQUINA Phase 1/2 Multi-Center, Open Label, Dose Escalation Study to Determine the Recommended Phase 2 Dose, Safety and Efficacy of the Antibody Drug Conjugate GSK2857916 in Combination with Pomalidomide and Low-Dose Dexamethasone in Subjects with Relapsed and/or Refractory Multiple Myeloma (MM)Mian, Dr HiraOpen to recruitmentNCT03715478
CMRG 008A Phase 2 Multi-Center, Open Label Study of Isatuximab added to standard CyBorD Induction and Lenalidomide Maintenance Treatments in Newly Diagnosed, Transplant Eligible Multiple MyelomaMian, Dr HiraOpen to recruitmentNCT04786028
(CCTG) LY.17A Multi-stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell LymphomaFraser, Dr GraemeSuspended/On holdNCT02436707
Foley, Dr RonanSuspended/On holdNCT04231747
(Kronos Bio) KB-ENTO-3001 / AGILITYA Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety
of Entospletinib in Combination With Intensive Induction and Consolidation Chemotherapy in
Adults With Newly Diagnosed Nucleophosmin 1-mutated Acute Myeloid Leukemia
Leber, Dr BrianSuspended/On holdNCT05020665
(Karyopharm) KCP-8602-801A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients With Relapsed/Refractory Cancer IndicationsKhalaf, Dr DinaSuspended/On holdNCT02649790
Download PDF